HOLLISTON, Mass., Feb. 22, 2018 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2017 after market trading hours on Thursday, March 1, 2018. A conference call to discuss the company's fourth quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-888-771-4371, or international: 1-847-585-4405, and referencing the conference ID# 46530979.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through March 8, 2018.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999


GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations
Anthropic IPO Marketing Expected to Start in Mid-October
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up
Shein Shares Drop 5% After Weak Hong Kong IPO Debut
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up
Audi, SAIC Launch China Innovation Hub for New AUDI Models
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall
Milei Threatens Falkland Oil Firms With Sanctions
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability
CATL Shares Fall as Hungary Plant Faces Safety Halt
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 



